

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

In re NEW PATENT Application of)
Tohru Natsume)
Application No. 10/581,969)
Filed: June 7, 2006)
National Stage of)
International Application No. PCT/JP04/18179)
International Filing Date: December 7, 2004)

For: NOVEL INTERACTION BETWEEN PROTEINS, AND THERAPEUTIC AGENT FOR
DISUSE MUSCULAR ATROPHY OR METHOD ASSOCIATED WITH DISUSE
MUSCULAR ATROPHY TAKING ADVANTAGE OF NOVEL INTERACTION

**SUBMISSION OF SEQUENCE LISTING AND
STATEMENT UNDER 37 CFR 1.821**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted in accordance with 37 CFR 1.821(c) and (e) is a paper copy of the
Sequence Listing set forth in the above-identified application.


Also submitted in accordance with 37 CFR 1.821(f) is a labeled diskette, containing
computer readable copy of this Sequence Listing.

STATEMENT UNDER 37 CFR 1.821(f)

Pursuant to 37 CFR 1.821(f), I the undersigned attorney for Applicants, hereby state
that the sequence listing information recorded in computer readable form is identical to the
written on paper sequence listing.

Respectfully submitted,

Date: April 4, 2007


Tohru Natsume